BHCM
HZNP

Brevan Howard Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Brevan Howard Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-45,000
Closed -$5.21M – 1123
2023
Q3 		$5.21M Hold
45,000
– – 0.07% 40
2023
Q2 		$4.63M Hold
45,000
– – 0.1% 35
2023
Q1 		$4.91M Buy
+45,000
New +$4.97M 0.13% 48

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Brevan Howard Capital Management's HZNP Position: Q4 2023 in Review

Brevan Howard Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 45,000 shares — an estimated $5.21M sold.

Brevan Howard Capital Management first reported a position in HZNP in Q1 2023 and held it in 3 quarters. The position peaked at $5.21M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Brevan Howard Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Brevan Howard Capital Management sold 45,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $5.21M.
  • Brevan Howard Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 3 quarters.
  • Brevan Howard Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.21M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Brevan Howard Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.